ONCOLOGY Nurse Edition April 2009, Vol 23 No 4

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Roman Fabbricatore

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Jorge Nieva, MD

July 14th 2025

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Russ Conroy

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

Tim Cortese

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

Related Content

Ariana Pelosci

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Roman Fabbricatore

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Jorge Nieva, MD

July 14th 2025

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Russ Conroy

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Tim Cortese